CN105878246A - Semi-synthetic antibiotic - Google Patents
Semi-synthetic antibiotic Download PDFInfo
- Publication number
- CN105878246A CN105878246A CN201510033584.7A CN201510033584A CN105878246A CN 105878246 A CN105878246 A CN 105878246A CN 201510033584 A CN201510033584 A CN 201510033584A CN 105878246 A CN105878246 A CN 105878246A
- Authority
- CN
- China
- Prior art keywords
- parts
- semi
- synthetic antibiotic
- rifampicin
- hair follicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of antibiotics, and in particular relates to a semi-synthetic antibiotic capable of inhibiting synthesis of RNA through conversion of bacteria DNA. The semi-synthetic antibiotic comprises tablets and a reagent, wherein the tablets comprise the following components in parts by weight: 0.2-0.3 part of rifampicin, and 0.09-0.10 part of isoniazide; and the reagent comprises the following components in parts by weight: 15-30 parts of glycerol, 10-25 parts of stearic acid, 0.5-1.5 parts of spice, and the balance water. The semi-synthetic antibiotic has strong inhibiting effects on leprosy bacillus and gram-positive bacteria, has inhibiting effects on the infection caused by staphylococcus aureus, and has certain inhibiting effects on gram-positive bacteria and viruses. Staphylococcus aureus invades from hair follicle or sweat glands so as to cause acute pyogenic infection of a single hair follicle or adipose glands of the single hair follicle, the inflammation usually expands to the subcutaneous tissue, and the semi-synthetic antibiotic has an obvious inhibiting effect on staphylococcus aureus.
Description
Technical field
The invention belongs to antibiotic technical field, specifically one and can face upward DNA of bacteria processed conversion
The semisynthetic antibiotics of synthesis RNA.
Background technology
Rifampicin Rifampin chemical name: 3-[[(4-methyl isophthalic acid-piperazinyl) imino group]
Methyl]-rifamycin.
Molecular formula: C43H58N4O12；Molecular weight: 822.95.
Isoniazid Isoniazid chemical name: Isoniazid.
Molecular formula: C6H7N3O molecular weight: 137.14
Above-mentioned active ingredient contacts can cause multi-medicament compatibility reaction, or can make respective medicine
React further between the catabolite of thing, such as the favourable good fortune of introducing impurity possible in rifampicin
Mycin SV, quinoid rifampicin, N aoxidize rifampicin and 3 formyl rifamycins etc., and these are changed
Compound mostly is synthesis precursor or the bigger composition of toxicity；And for example free hydrazine in isoniazid, in storage
During easily degrade.
Accordingly, it would be desirable to technical progress, the improvement of chemical formulation component, reach to solve
State the purpose of problem.
Summary of the invention
The invention aims to solve deficiency of the prior art, it is provided that one can face upward system
The semisynthetic antibiotics of DNA of bacteria Synthesis RNA.
The present invention includes that tablet and reagent, described tablet include rifampicin and isoniazid；Described
Reagent include glycerol, stearic acid, spice and water；Described rifampicin 0.2-0.3 part, institute
The isoniazid 0.09-0.10 part stated.
Preferably, described glycerol 15-30 part；Described stearic acid 10-25 part；Described perfume (or spice)
Material 0.5-1.5 part, surplus is water.
Preferably, described rifampicin 0.25 part, described isoniazid 0.095 part.
Preferably, described glycerol 20 parts；Described stearic acid 15 parts；Described spice 1 part.
Preferably, described water is 60 parts.
The present invention is a kind of semisynthetic antibiotics that can face upward DNA of bacteria Synthesis RNA processed,
Relatively strong to leprosy bacillus and cymbidium positive bacteria effect, the infection causing gold-coloured staphylococci has
Inhibition, has certain inhibitory action to Cao Lanshi positive bacteria and virus.Due to golden yellow Portugal
The hair follicle of grape coccus body becomes antiperspirant arteries and veins to invade the acute of the single hair follicle that causes and affiliated adipose gland thereof
Pyogenic infection, inflammation often expands to subcutaneous tissue, and staphylococcus aureus is had bright by this product
Aobvious inhibition.It addition, the present invention is practical, manufacturing cost is the highest, is suitable in phase
Pass technical field is promoted the use of.
Detailed description of the invention
Understandable for enabling the above-mentioned purpose of the present invention, feature and advantage to become apparent from, below right
The detailed description of the invention of the present invention is described in detail, make the present invention above and other purpose,
Feature and feature will become apparent from.
Embodiment one:
Semisynthetic antibiotics, including tablet and reagent, described tablet includes rifampicin and different cigarette
Hydrazine；Described reagent includes glycerol, stearic acid, spice and water；Described rifampicin 0.25
Part, described isoniazid 0.095 part.
Described glycerol 20 parts；Described stearic acid 15 parts；Described spice 1 part.
Excess water is 60 parts.
Embodiment two:
Semisynthetic antibiotics, including tablet and reagent, described tablet includes rifampicin and different cigarette
Hydrazine；Described reagent includes glycerol, stearic acid, spice and water；Described rifampicin 0.28
Part, described isoniazid 0.093 part.
Described glycerol 25 parts；Described stearic acid 19 parts；Described spice 1.3 parts.
Excess water is 60 parts.
Embodiment three:
Semisynthetic antibiotics, including tablet and reagent, described tablet includes rifampicin and different cigarette
Hydrazine；Described reagent includes glycerol, stearic acid, spice and water；Described rifampicin 0.23
Part, described isoniazid 0.094 part.
Described glycerol 16 parts；Described stearic acid 24 parts；Described spice 1.1 parts.
Excess water is 60 parts.
Effect of the present invention: heat clearing and inflammation relieving, heat-clearing and toxic substances removing, infection, Chinese medicine antiinflammatory, anti-post
Infested, impetigo, abscess and shallow table bacterial skin infection, all have antibacterial for pathogenic microorganism
Activity.
Obviously, described above elaborates a lot of detail so that fully understanding the present invention's
Technical scheme.But above description is only presently preferred embodiments of the present invention, and the present invention can
Implementing being much different from alternate manner described here, therefore the present invention is not disclosed above
The restriction being embodied as.The most any those skilled in the art are without departing from skill of the present invention
In the case of art aspects, all may utilize the method for the disclosure above and technology contents to skill of the present invention
Art scheme makes many possible variations and modification, or is revised as the equivalence enforcement of equivalent variations
Example.Every content without departing from technical solution of the present invention, according to the present invention technical spirit to
Any simple modification, equivalent variations and the modification that upper embodiment is done, all still falls within skill of the present invention
In the range of the protection of art scheme.
Claims (5)
1. a semisynthetic antibiotics, including tablet and reagent, it is characterised in that described tablet
Including rifampicin and isoniazid；Described reagent includes glycerol, stearic acid, spice and water；
Described rifampicin 0.2-0.3 part, described isoniazid 0.09-0.10 part.
A kind of semisynthetic antibiotics the most according to claim 1, it is characterised in that described
Glycerol 15-30 part；Described stearic acid 10-25 part；Described spice 0.5-1.5 part is remaining
Amount is water.
A kind of semisynthetic antibiotics the most according to claim 1, it is characterised in that described
Rifampicin 0.25 part, described isoniazid 0.095 part.
A kind of semisynthetic antibiotics the most according to claim 2, it is characterised in that described
Glycerol 20 parts；Described stearic acid 15 parts；Described spice 1.0 parts.
A kind of semisynthetic antibiotics the most according to claim 2, it is characterised in that described
Excess water 60 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510033584.7A CN105878246A (en) | 2015-01-22 | 2015-01-22 | Semi-synthetic antibiotic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510033584.7A CN105878246A (en) | 2015-01-22 | 2015-01-22 | Semi-synthetic antibiotic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105878246A true CN105878246A (en) | 2016-08-24 |
Family
ID=56999466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510033584.7A Pending CN105878246A (en) | 2015-01-22 | 2015-01-22 | Semi-synthetic antibiotic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878246A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021189444A1 (en) * | 2020-03-24 | 2021-09-30 | 中国人民解放军海军军医大学 | Use of rifamycin antibiotics in preparation of drugs against yellow fever virus infections |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1611218A (en) * | 2003-10-31 | 2005-05-04 | 沈阳药科大学 | Fixed dose compound preparation of antitubercular drug and its preparing method |
| CN102920707A (en) * | 2012-11-02 | 2013-02-13 | 沈阳药科大学 | Process for preparing compound antituberculous preparation |
-
2015
- 2015-01-22 CN CN201510033584.7A patent/CN105878246A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1611218A (en) * | 2003-10-31 | 2005-05-04 | 沈阳药科大学 | Fixed dose compound preparation of antitubercular drug and its preparing method |
| CN102920707A (en) * | 2012-11-02 | 2013-02-13 | 沈阳药科大学 | Process for preparing compound antituberculous preparation |
Non-Patent Citations (2)
| Title |
|---|
| SANOFI: "Rifinah® 300/150mg Film-coated Tablets", 《HTTP://WWW.HPRA.IE/IMG/UPLOADED/SWEDOCUMENTS/2132257.PA0540_068_002.2C46E4B2-86F2-4BCA-A67B-D08D351121B2.000001RIFINAH%20300-150MG%20-%20APPROVED%20PL.130620.PDF》 * |
| 姚静: "《药用辅料应用指南》", 30 August 2011, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021189444A1 (en) * | 2020-03-24 | 2021-09-30 | 中国人民解放军海军军医大学 | Use of rifamycin antibiotics in preparation of drugs against yellow fever virus infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dos Santos et al. | In vitro e in silico evaluation of the inhibition of Staphylococcus aureus efflux pumps by caffeic and gallic acid | |
| CN102702184B (en) | Oxazolidinone derivative | |
| WO2007023507A3 (en) | Oxazolidinones bearing antimicrobial activity composition and methods of preparation | |
| CN1325504C (en) | Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids | |
| KR102655551B1 (en) | Compounds affecting pigment production and their uses for the treatment of bacterial infections | |
| WO2004062601A3 (en) | Antibacterial agents | |
| CA2367017A1 (en) | Inhibitors of impdh enzyme | |
| WO2002048147A3 (en) | Pyrazolopyridines | |
| WO2008023248A3 (en) | Novel macrolides and ketolides having antimicrobial activity | |
| WO2002062767A1 (en) | Novel quinazoline derivatives | |
| WO2004011477A3 (en) | 6,11-4-carbon bridged ketolides | |
| BG105865A (en) | 6-o-substituted macrolides having antibacterial activity | |
| Wang et al. | Cadiolides J–M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja | |
| WO2012017434A3 (en) | Guanine nucleotide derivatives for treating bacterial infections | |
| CN105878246A (en) | Semi-synthetic antibiotic | |
| WO2003089446A3 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
| WO2004087652A3 (en) | Imidazotriazine compounds | |
| TW200608967A (en) | Pharmaceutical compositions containing with diabetic agent | |
| WO2004007489A3 (en) | Antibacterial substituted cyanomethyl (ene) piperidinophenyl oxazolidinones, process or their preparation, and pharmaceutical compositions containing them | |
| ES8301274A1 (en) | Peptide antibiotic, component B, process for its preparation and its use in medicines. | |
| CN103059045B (en) | Novel amoxicillin sodium and clavulanate potassium compound and pharmaceutical composition thereof | |
| WO2006079896A3 (en) | Stable polyol formulations of oxazolidinone antibacterial agents | |
| Ramón et al. | Mechanisms of action of quinolones against staphylococci and relationship with their in vitro bactericidal activity | |
| Mortazavi et al. | Antimicrobial and Antibiofilm Activity of 4-Benzylidene-2-methyl-oxazoline-5-one against Pathogen Bacteria | |
| CN111094262A (en) | 1, 3-dioxane-4, 6-diketone compound, preparation method thereof, pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160824 |
|
| WD01 | Invention patent application deemed withdrawn after publication |